Search

CN-121991863-A - Fermented lactobacillus mucilaginosus, composition and application

CN121991863ACN 121991863 ACN121991863 ACN 121991863ACN-121991863-A

Abstract

The invention discloses a fermented lactobacillus mucilaginosus, a composition and application. The fermented lactobacillus is classified and named as fermented lactobacillus Limosilactobacillus fermentum, the strain number ZD-011, and the preservation number CCTCC NO is M20251136. The strain has dual activities of promoting theanine absorption and resisting depression. The fermentation lactobacillus mucilaginosus ZD-011 and theanine have a synergistic action mode, namely the antidepressant effect generated by the combination of the two is obviously superior to the sum of the effects of the independent use of the two, and a novel and more advantageous combination scheme is provided for developing high-efficiency compound antidepressant products. The strain and the composition are all derived from nature, have high safety, avoid a plurality of side effects of traditional chemical medicines, can be widely applied to the fields of functional foods, health-care foods, special medical foods, auxiliary therapeutic medicines and the like, and have wide market prospect and social value.

Inventors

  • LIU JUNSHENG
  • HUANG JIAHONG
  • ZHANG LUQING

Assignees

  • 浙江大学

Dates

Publication Date
20260508
Application Date
20260409

Claims (9)

  1. 1. A fermented lactobacillus mucilaginosus is characterized in that the classification is named as fermented lactobacillus mucilaginosus Limosilactobacillusfermentum, the strain number is ZD-011, and the preservation number is CCTCC NO: M20251136.
  2. 2. Use of the fermented lactobacillus mucilaginosus according to claim 1 for the preparation of antidepressant products.
  3. 3. The use according to claim 2, wherein the product is a pharmaceutical product, a health food or a feed.
  4. 4. A composition comprising theanine and the lactobacillus mucilaginosus of claim 1.
  5. 5. The composition of claim 4, wherein each 1.2mg of theanine corresponds to 1 x 10 7 ~1×10 11 CFU of live lactobacillus mucilaginosus.
  6. 6. The composition of claim 4, further comprising a pharmaceutically or dietetically acceptable carrier and/or prebiotic.
  7. 7. The composition of claim 4, wherein the dosage form is a powder, granule, capsule, tablet, oral liquid or fermented food.
  8. 8. Use of a composition according to any one of claims 4 to 7 for the preparation of an antidepressant product.
  9. 9. The use according to claim 8, wherein the product is a pharmaceutical product, a health food or a feed.

Description

Fermented lactobacillus mucilaginosus, composition and application Technical Field The invention belongs to the technical field of biology, and particularly relates to a fermented lactobacillus mucilaginosus, a composition and application. Background Depression is a common mood disorder with high global morbidity and serious harm to human physical and mental health. Currently, mainstream therapeutic drugs (such as SSRIs) often have various side effects such as delayed onset of action, sexual dysfunction, weight gain, and the like, and patient compliance is poor. Therefore, the development of safe, effective replacement or adjuvant therapies is of great importance. Theanine (Theanine) is a unique non-protein amino acid in tea, and a great deal of researches show that the Theanine has the physiological functions of relieving anxiety, improving sleep and stabilizing emotion and has extremely high safety. However, theanine has relatively limited bioavailability after oral administration and large individual differences, which affect stable exertion of its efficacy and determination of optimal dosage. In recent years, the theory of "brain-gut axis" provides a new perspective for the treatment of mental diseases. Intestinal probiotics improve host emotion and behavior by regulating the immune system, reducing inflammatory levels, producing neuroactive metabolites (e.g., gamma-aminobutyric acid, short chain fatty acids), and affecting multiple mechanisms of vagal signaling. In addition, some probiotic strains have been shown to be capable of altering the metabolic state of the host, enhancing digestion, absorption and utilization of specific nutrients. The invention application with publication number of CN116814464A discloses a fermented lactobacillus mucilaginosus JF5 and application thereof in preparing lipid-reducing and digestion-aiding food and medicine, and the lactobacillus has the probiotic functions of promoting digestion and absorption of protein food to improve protein allergy, promoting absorption of cellulose to improve constipation, resisting depression and alcohol, resisting aging and wrinkle, reducing blood sugar, promoting intestinal absorption and peristalsis and the like. The invention application with publication number CN119700832A discloses application of a fermentation lactobacillus mucilaginosus strain A21196 in preparing products for resisting anxiety and improving memory and concentration, wherein the fermentation lactobacillus mucilaginosus strain A21196 has the effects of resisting anxiety, resisting depression and improving cognitive dysfunction and improving memory concentration. The invention application with the publication number of CN119876281A discloses application of lactobacillus mucilaginosus B14.32 in fermenting traditional Chinese medicines and an antidepressant traditional Chinese medicine fermentation composition, combines a microbial fermentation technology with traditional Chinese medicine extraction, utilizes lactobacillus mucilaginosus B14.32 and saccharomycetes to perform two-step fermentation on traditional Chinese medicines with antidepressant effect, obtains the antidepressant traditional Chinese medicine fermentation composition, preserves active ingredients of the traditional Chinese medicines to the maximum extent, enhances the efficacy and reduces the toxicity, and the obtained antidepressant traditional Chinese medicine fermentation composition has the functions of resisting depression and relieving brain inflammation of depression patients. However, at present, the research on compounding probiotics and theanine is mostly based on simple superposition of independent functions of the probiotics and the theanine, and the discovery and development of specific probiotics strains which can generate clear synergistic effect with the theanine and have antidepressant activity are lacking. For example, the invention application with publication number of CN113332318A discloses a pharmaceutical composition with the efficacy of improving depression symptoms and a preparation method thereof, wherein the composition contains 50-80% of flammulina velutipes de-enzyming water extract, 1-3% of theanine, 1-10% of probiotics, 5-30% of prebiotics, 5-10% of sugar substitutes and a pharmaceutically acceptable carrier. The probiotics are selected from any one or combination of lactobacillus casei, saccharomycetes, probiotics spore fungus, clostridium butyricum, lactobacillus, bifidobacterium lactis, streptococcus thermophilus and actinomycetes. Disclosure of Invention The invention obtains a strain of fermented lactobacillus mucilaginosus with dual activities of promoting theanine absorption and resisting depression by itself through screening. The invention firstly provides a fermented lactobacillus mucilaginosus, which is classified and named as fermented lactobacillus mucilaginosus Limosilactobacillus fermentum, strain number ZD-011, and preservation number CCTCC NO: M20251136.